Molecular mechanisms of targeted cancer treatments

Friday 04 December 2020, Royal Marsden Hospital London

Level: Advanced

Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine’s other courses

Description: This course covers a wide range of licensed and experimental cancer treatments for solid tumours, explaining their mechanism of action at a molecular and cellular level. It also contains detailed information on mechanisms of drug resistance and discusses the future of personalised cancer medicine.

To book, contact: conferenceteam@rmh.nhs.uk Tel. 020 7808 2922

Programme

Targeted cancer treatments: the current landscape

  • Where have we got to?
  • Hallmarks of cancer cells – choose your target
  • Cancer and the immune system

The main classes of current targeted treatments:

  • Monoclonal antibody (mAb) technology
  • Small molecule kinase inhibitors

Immunotherapy

  • Checkpoint inhibitors
  • CAR T cell therapy
  • Peptide vaccines and oncolytic viruses

Targeting cell communication pathways

  • Inhibitors of EGFR and  HER2
  • PI3K, AKT & mTOR inhibitors
  • B-RAF & MEK inhibitors
  • Drug resistance mechanisms

Angiogenesis, PARP and CDK inhibitors

  • VEGFR/angiogenesis inhibitors
  • PARP inhibitors
  • CDK inhibitors for hormone-sensitive breast cancer

Biomarkers and personalised cancer treatment

  • The use of biomarkers to select patients for trials and treatments for patients
  • Progress in biomarkers for checkpoint inhibitors